Highlights in review
Innovation award
The lung cancer risk screening product built on ProteinT's independently developed n-LAPE/MSTMplatformreceived the "2023 Tumor Biomarker Innovative Technology Product Award"
. The product screens for protein biomarkers associated with the occurrence and development of lung cancer and, through a big-data lung cancer risk model, calculates a risk score to assess the subject's lung cancer risk — full recognition of the innovative and advanced nature of ProteinT's technology.
Product portfolio
A novel biomarker discovery platform for liquid biopsy based on next-generation nano-scale low-abundance protein enrichment mass spectrometry n-LAPE/MSTM
Multiple self-developed products certified by NMPA
Several of ProteinT's self-developed, mass-spectrometry-platform-based proteomicsfull-process testing products have obtained NMPA registration certificates
, laying a solid foundation for bringing proteomics into clinical service and leading clinical mass spectrometry testing in proteomics into an era of standardization.A generous tenth-anniversary gift — Free T
